Molecular diagnostics: An FDA perspective

Ali M. Ardekani, Emanuel F. Petricoin, Joseph L. Hackett*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


The potential medical applications of microarrays and in vitro diagnostic devices for global assessments of DNA sequence variations, relative RNA abundance and measurements of proteins have generated much excitement, and some skepticism, within the biomedical community. It has been suggested that within the next decade these microarrays and diagnostic devices will be routinely used in the selection, assessment and quality control of the best drugs for pharmaceutical development, at the bedside for diagnostics and for clinical monitoring of both desired and adverse outcomes of therapeutic interventions. Realizing such potential will be a challenge to the entire scientific community as often breakthroughs which show great promise at the bench fail to meet the requirements of clinicians and regulatory scientists, and to make the transition into common clinical and regulatory practice. The development of a co-operative framework between regulators, product sponsors and technology experts will be essential for realizing the revolutionary promise these platforms could have on the evolution of drug development, regulatory science, the practice of medicine and public health.

Original languageEnglish
Pages (from-to)129-140
Number of pages12
JournalExpert Review of Molecular Diagnostics
Issue number2
StatePublished - Mar 2003
Externally publishedYes


  • Diagnostics
  • FDA
  • Microarrays


Dive into the research topics of 'Molecular diagnostics: An FDA perspective'. Together they form a unique fingerprint.

Cite this